Opportunities in the North America molecular diagnostics market include rising demand due to increased chronic and infectious diseases, advances in point-of-care testing, and next-generation ...
Gilead beats Q4 estimates on strong HIV and Liver Disease portfolio performance, but 2026 guidance tempers sentiment despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results